For Joined Up Thinking Buy Piracetam Nootropil

Piracetam is the original Nootropic or Smart drug designed to improve memory, enhance your brain functions and stimulate the central nervous system. Originally developed in the 1960’s, Piracetam has been is use primarily in Europe ever since and is known for its non-toxic and non-addictive properties.

What Will Piracetam Do For Me?

Piracetam is an effective cognitive enhancer that has been used successfully to treat a wide range of conditions and been shown to increase a person’s attention levels and improve memory and intelligence.

Piracetam also helps to slow down ‘senile involution’, dementia and Alzheimer’s disease. In tests and trials, Piracetam showed significant improvement in memory consolidation and recall in elderly out-patients suffering from ‘age-associated memory impairment’.

Piracetam has also been used to improve patient’s recovery from strokes particularly improving post stroke speech impairment (aphasia). Another use has been in cases of acute and chronic cerebral ischaemia, which is decreased blood flow to the brain. Taking Piracetam restored speech and the use of limbs in these patients, it also increased neuronal activity in the brain when measured with Electroencephalography (EEG).

How does Piracetam work?

Piracetam works on the Corpus Callosum, the region of the brain that links the two hemispheres. It is this action which most experts believe is the key that gives Piracetam users the ability to channel greater brain potential by connecting the logical side of the brain with the creative side more effectively.

What Dosage of Piracetam Should I Take?

A common dose is three Nootropil 800mg tablets twice a day, then lowering to one or two Nootropil 800 tablets twice a day after the first month.

Please note the effect of Piracetam can be increased if taken with DMAE, Centrophenoxine, Choline or Hydergine. When Choline and Piracetam are taken together there is a synergistic effect that causes a greater improvement in memory than when taken alone.

Side effects are minimal and seldom experienced.

Piracetam The Original Smart Drug

Piracetam is a trusted and versatile smart drug and stimulates a key part of the brain, to give you a safe, non-toxic, non-addictive mental boost. Piracetam was one of the first products antiaging systems stocked and it remains one of the most popular over twenty years later!

Antiaging-systems.com can now offer a new version of Piracetam, called Pira Pro. In the larger pack size of 100 x 800mg tablets, and priced at just $17.99 it shows remarkable value for money.

[productalsobuy]

What our customers say...

Nootropics may increase learning and memory in healthy individuals through a distinctive power to promote what has been termed hemispheric-super-connection.
S.J. Dimond et al , "Effects of nootropics" Psycopharmacol. 64, 1979 341-348.

"My doctor recommended IAS & their products when he prescribed me Piracetam. The packaging for the Piracetam tablets is fabulous & the tablets are really easy to remove. I have been ordering for many years & have been very pleased with the products & their services."

Video

Piracetam The original smart drug

Labels

Piracetam Nootropil Liquid – The Smart Choice Of Brain-Enhancing Supplement

Nootropil liquid is part of a group of so-called 'smart drugs' that are renowned for boosting and protecting brain function. It has proven and profound anti-aging properties, including the capacity to improve memory, stimulate the nervous system, and increase attention span.

Nootropil liquid has been shown to build and maintain the corpus callosum, which links the left and right sides of our brains. This helps treat a number of various conditions, from alcoholism to strokes. The active ingredient Piracetam meanwhile protects against age-related cognitive conditions such as Alzheimer’s disease.

Nootropil liquid solution contains 20% Piracetam. As such, dosage must be monitored carefully, and special care must be taken if used in conjunction with other medication. Side effects may include fatigue, intestinal disorders, dizziness, and occasional weight gain.

PIRACETAM / NOOTROPIL® 20% LIQUID

IN THIS TRANSLATION:

  • What Nootropil 20% solution is and what it is used for.
  • Before taking Nootropil 20% solution.
  • How to take Nootropil 20% solution.
  • Possible side effects.
  • Storing Nootropil 20% solution.

The active ingredient is Piracetam (I.N.N.) 800 mg /4 ml. The other ingredients are: glycerol (E422), sodium saccharine, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), apricot aroma, caramel aroma, sodium acetate, acetic acid, purified water.

WHAT NOOTROPIL 20% SOLUTION IS AND WHAT IT IS USED FOR:
Nootropil 20% solution is a Nootropic substance and has no sedative or psychostimulating effects. It is recommended for the treatment of attention and memory disorders, difficulties in daily activity and adaptation to one’s environment, states which accompany mental deterioration owing to an age-related neurodegenerative illness.

BEFORE TAKING NOOTROPIL 20% SOLUTION:
Do not take Nootropil 20% solution if -

  • If you are hypersensitive to Piracetam or any of the ingredients in this preparation.
  • If you are suffering from a brain hemorrhage.
  • If you are suffering from terminal kidney failure.

Be especially careful with Nootropil 20% solution:
If you suffer from kidney problems, take a lower dose in accordance with the seriousness of these problems. Your physician will tell you what dosage to take. Abrupt suspension of treatment should be avoided in myoclonic patients since this can cause a myoclonic or generalized crisis.

Pregnancy:
Consult your physician or pharmacist before taking any pharmaceutical drug. Even though no side effects have been reported in animal studies, do not take Nootropil 20% solution during pregnancy. Should you accidentally swallow Nootropil 20% solution, it is not expected that the fetus will be harmed.

Breast-feeding:
Consult your physician or pharmacist before taking any pharmaceutical drug. Avoid using Nootropil 20% solution during breast-feeding or refrain from breast-feeding during treatment.

Driving and operating machinery:
Taking into account the possible side effects reported with Nootropil 20% solution, remember that these may affect your capacity for driving and operating machinery.

The elderly:
Elderly patients are advised to see their physician on a regular basis to monitor their dosage.

Important information concerning some of the ingredients in Nootropil 20% solution: Because this medicine contains glycerol as an excipient, it may be harmful in high dosages, causing headaches, upset stomach or diarrhea.

When taking other pharmaceutical drugs:
Inform your physician or pharmacist if you are taking or have recently taken other pharmaceutical drugs, including those sold without prescription. A single case has been reported in which the concomitant use of Piracetam and thyroid hormone extracts (T3 and T4) has caused confusion, irritability and sleeping disorders. No further interactions with other medicines have been reported to date.

HOW TO TAKE NOOTROPIL 20% SOLUTION
Always follow the dosage of Nootropil 20% solution that your physician has prescribed for you. If you have any doubts or questions, consult your physician or pharmacist. Nootropil 20% solution is taken orally, with or without food. The usual dosage is: For the symptomatic treatment of states of mental deterioration: Start treatment by taking 4.8 g of Piracetam (6 x 4-ml doses of the solution) daily during the first few weeks, decreasing the dosage to 2.4 g of Piracetam (3 x 4-ml doses of the solution) daily. This should be taken in 2-3 doses. For the treatment of cortical myoclonias: Start treatment with a daily dosage of 7.2 g of Piracetam (9 x 4-ml doses of the solution) and increase the daily dosage by 4.8 g of Piracetam (6 x 4-ml of the solution), every 3-4 days until obtaining a satisfactory response, or up to a maximum daily dosage of 24 g of Piracetam. The daily dosage should be broken down into 2-3 doses, continuing the regular dosage of other anti-myoclonic treatments. Later, depending on the clinical response obtained, reduce the dosage of the other anti-myoclonic drugs if possible. Once treatment with Nootropil 20% solution has begun, it should be continued for as long as the cerebral pathology persists. Nonetheless, every 6 months an effort should be made to reduce or stop treatment. Note: Patients suffering from kidney problems should take a lower dosage (see- Be especially careful with Nootropil 20% solution). The length of treatment depends on the type, duration and evolution of the symptoms. If you believe that the effect of Nootropil 20% solution is too severe or too mild, consult your physician or pharmacist. Directions for use: The dose of the solution can be taken alone or diluted with a little water. If you take more Nootropil 20% solution than you should: If you or another person takes an overdose of Nootropil 20% solution, inform your physician, who will inform you of the measures to be taken. In the case of overdose or accidental ingestion, consult a physician or local toxicology office. If you forgot to take Nootropil 20% solution: Do not take a double dose to compensate for the forgotten dose. Continue your usual dosage as scheduled. Effects to expect when interrupting the dosage of Nootropil 20% solution: To prevent the abrupt reappearance of the disorder, gradually reduce the dosage by 1.2 g of Piracetam (6 ml of solution) every 2 days.

POSSIBLE SIDE EFFECTS:
In addition to the beneficial effects of Nootropil 20% solution, unpleasant side effects may also be produced, even when the medicine is properly used. The adverse side-effects reported with Nootropil 20% solution are trembling, weight gain, nervousness, drowsiness, depression and fatigue. The incidence of side effects in controlled studies is under 2% and these have generally occurred with a daily dosage of over 2.4 g of Piracetam (3 x 4-ml doses of solution) in elderly patients. In the majority of cases, such symptoms subside with a lowered dosage. Occasional cases have also reported of dizziness, intestinal disorders (nausea, vomiting, diarrhea, upset stomach), hypersensitive reactions, lack of coordination, loss of balance, aggravation of epilepsy, headache, insomnia, jumpiness, anxiety, confusion, hallucinations and skin reactions. Very rare cases have been reported of localized pain, thrombophlebitis, fever and lowered blood pressure. If you notice any of these unpleasant side effects, inform your physician so that he or she can assess the severity of the side effect and decide if it is necessary to take any measure should be taken. If you notice unpleasant side effects not mentioned in this insert, report it to your physician or pharmacist.

STORING NOOTROPIL 20% SOLUTION:
Keep Nootropil 20% solution out of children’s reach and sight. No special storage conditions are required. Do not use this pharmaceutical drug after the expiry date shown on the box and bottle.

EXPIRY:
This drug should not be used once the expiry date shown on the box has elapsed.

KEEP ALL PHARMACEUTICAL PRODUCTS OUT OF THE REACH OF CHILDREN.


The above information is the translation of the manufacturer's insert. It is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.

Nootropil 800 mg film-coated Tablets

2. Qualitative and quantitative composition

Piracetam - 800 mg per tablet

3. Pharmaceutical form

Tablet for oral administration.

4. Clinical particulars
4.1 Therapeutic indications

Adults:

NOOTROPIL is indicated for patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies.

4.2 Posology and method of administration

The daily dosage should begin at 7.2 g increasing by 4.8 g every three to four days up to a maximum of 24 g, in two or three sub-doses. Treatment with other anti-myoclonic medicinal products should be maintained at the same dosage. Depending on the clinical benefit obtained, the dosage of other such medicinal products should be reduced, if possible.

Once started, treatment with piracetam should be continued for as long as the original cerebral disease persists. In patients with an acute episode, spontaneous evolution may occur over time and an attempt should be made every 6 months to decrease or discontinue the medicinal treatment. This should be done by reducing the dose of piracetam by 1.2 g every two days (every three or four days in the case of a Lance and Adams syndrome, in order to prevent the possibility of sudden relapse or withdrawal seizures).

Elderly

Adjustment of the dose is recommended in elderly patients with compromised renal function (see 'Dosage adjustment in patients with renal impairment' below). For long term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed.

Patients with renal impairment

The daily dose must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination using the following formula:

Group

Creatinine Clearance (ml/min)

Posology and frequency

Normal

> 80

usual daily dose, 2 to 4 sub-doses

Mild

50-79

2/3 usual daily dose, 2 or 3 sub-doses

Moderate

30-49

1/3 usual daily dose, 2 sub-doses

Severe

< 30

1/6 usual daily dose, 1 single intake

End-stage renal disease

--

contraindicated

Patients with hepatic impairment

No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of dose is recommended (see 'Dosage adjustment in patients with renal impairment' above).

Method of administration

Piracetam should be administered orally, and may be taken with or without food. The tablet(s) should be swallowed with liquid. It is recommended to take the daily dose in two to four sub-doses.

4.3 Contraindications

Piracetam is contra-indicated in patients with severe renal impairment (renal creatinine clearance of less than 20 ml per minute). It is also contraindicated in patients with cerebral haemorrhage, suffering from Huntington's Chorea and in those with hypersensitivity to piracetam, other pyrrolidone derivatives or any of the excipients.

4.4 Special warnings and precautions for use

Effects on platelet aggregation

Due to the effect of piracetam on platelet aggregation (see section 5.1), caution is recommended in patients with severe haemorrhage, patients at risk of bleeding such as gastrointestinal ulcer, patients with underlying disorders of haemostasis, patients with history of haemorrhagic CVA, patients undergoing major surgery including dental surgery, and patients using anticoagulants or platelet antiaggregant drugs including low dose aspirin

Renal insufficiency

Piracetam is eliminated via the kidneys and care should thus be taken in cases of renal insufficiency (see section 4.2).

Elderly

For long-term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed (see section 4.2).

Discontinuation

Abrupt discontinuation of treatment should be avoided as this may induce myoclonic or generalised seizures in some myoclonic patients.

Warnings related to the excipients

This product contains about 2 mmol (or about 46 mg) sodium per 24 g piracetam. To be taken into consideration by patients on a controlled sodium diet.

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacokinetics interactions

The drug interaction potential resulting in changes of piracetam pharmacokinetics is expected to be low because approximately 90% of the dose of piracetam is excreted in the urine as unchanged drug.

In vitro, piracetam does not inhibit the human liver cytochrome P450 isoforms CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 4A9/11 at concentrations of 142, 426 and 1422 µg/ml.

At 1422 µg/ml, minor inhibitory effects on CYP 2A6 (21%) and 3A4/5 (11%) were observed. However, the Ki values for inhibition of these two CYP isoforms are likely to be well in excess of 1422 µg/ml. Therefore, metabolic interaction of piracetam with other drugs is unlikely.

Thyroid hormones

Confusion, irritability and sleep disorder have been reported during concomitant treatment with thyroid extract (T3 + T4).

Acenocoumarol

In a published single-blind study on patients with severe recurrent venous thrombosis, piracetam 9.6 g/d did not modify the doses of acenocoumarol necessary to reach INR 2.5 to 3.5, but compared with the effects of acenocoumarol alone, the addition of piracetam 9.6 g/d significantly decreased platelet aggregation, β-thromboglobulin release, levels of fibrinogen and von Willebrand's factors (VIII : C; VIII : vW : Ag; VIII : vW : RCo) and whole blood and plasma viscosity.

Antiepileptic drugs

A 20 g daily dose of piracetam over 4 weeks did not modify the peak and trough serum levels of antiepileptic drugs (carbamazepine, phenytoin, phenobarbitone, valproate) in epileptic patients who were receiving stable doses.

Alcohol

Concomitant administration of alcohol had no effect on piracetam serum levels and alcohol levels were not modified by a 1.6 g oral dose of piracetam.

4.6 Pregnancy and lactation

Pregnancy

There are no adequate data from the use of piracetam in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal / foetal development, parturition or post-natal development (see section 5.3).

Piracetam crosses the placental barrier. Drug levels in the newborn are approximately 70% to 90% of maternal levels. Piracetam should not be used during pregnancy unless clearly necessary, when benefit exceeds the risks and the clinical condition of the pregnant mother requires treatment with piracetam.

Lactation

Piracetam is excreted in human breast milk. Therefore, piracetam should not be used during breastfeeding or breastfeeding should be discontinued, while receiving treatment with piracetam. A decision must be made whether to discontinue breast-feeding or to discontinue piracetam therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

4.7 Effects on ability to drive and use machines

In clinical studies, at dosages between 1.6 - 15 grams per day, hyperkinesia, somnolence, nervousness and depression were reported more frequently in patients on piracetam than on placebo. There is no experience on driving ability in dosages between 15 and 20 grams daily. Caution should therefore be exercised by patients intending to drive or use machinery whilst taking piracetam.

4.8 Undesirable effects

a. Summary of safety profile

Double-blind placebo-controlled clinical or pharmacoclinical trials, of which quantified safety data are available (extracted from the UCB Documentation Data Bank on June 1997), included more than 3000 subjects receiving piracetam, regardless of indication, dosage form, daily dosage or population characteristics.

b. Tabulated list of adverse reactions

Undesirable effects reported in clinical studies and from post-marketing experience are listed in the following table per System Organ Class and per frequency. The frequency is defined as follows: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000).

Data from post-marketing experience are insufficient to support an estimate of their incidence in the population to be treated.

Blood and Lymphatic disorders

Not known: haemorrhagic disorder

Immune system disorders:

Not known: anaphylactoid reaction, hypersensitivity

Psychiatric disorders:

Common: nervousness

Uncommon: depression

Not known: agitation, anxiety, confusion, hallucination

Nervous system disorders:

Common: hyperkinesia

Uncommon: somnolence

Not known: ataxia, balance impaired, epilepsy aggravated, headache, insomnia,

Ear and labyrinth disorders:

Not known: vertigo

Gastrointestinal disorders:

Not known: abdominal pain, abdominal pain upper, diarrhoea, nausea, vomiting

Skin and subcutaneous tissue disorders:

Not known: angioneurotic oedema, dermatitis, pruritus, urticaria

General disorders and administration site conditions:

Uncommon: asthenia

Investigations

Common: weight increased

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard

4.9 Overdose

Symptoms

No additional adverse events specifically related to overdose have been reported with piracetam.

The highest reported overdose with piracetam was oral intake of 75 g. Bloody diarrhoea with abdominal pain, was most probably related to the extreme high dose of sorbitol contained in the used formulation.

Management of overdose

In acute, significant overdosage, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for overdose with piracetam. Treatment for an overdose will be symptomatic treatment and may include hemodialysis. The extraction efficiency of the dialyser is 50 to 60% for piracetam.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Piracetam's mode of action in cortical myoclonus is as yet unknown.

Piracetam exerts its haemorrheological effects on the platelets, red blood cells, and vessel walls by increasing erythrocyte deformability and by decreasing platelet aggregation, erythrocyte adhesion to vessel walls and capillary vasospasm.

- Effects on the red blood cells:

In patients with sickle cell anaemia, piracetam improves the deformability of the erythrocyte membrane, decreases blood viscosity, and prevents rouleaux formation.

- Effects on platelets:

In open studies in healthy volunteers and in patients with Raynaud's phenomenon, increasing doses of piracetam up to 12 g was associated with a dose-dependent reduction in platelet functions compared with pre-treatment values (tests of aggregation induced by ADP, collagen, epinephrine and ßTG release), without significant change in platelet count. In these studies, piracetam prolonged bleeding time.

- Effects on blood vessels:

In animal studies, piracetam inhibited vasospasm and counteracted the effects of various spasmogenic agents. It lacked any vasodilatory action and did not induce “steal”phenomenon, nor low or no reflow, nor hypotensive effects.

In healthy volunteers, piracetam reduced the adhesion of RBCs to vascular endothelium and possessed also a direct stimulant effect on prostacycline synthesis in healthy endothelium.

-Effects on coagulation factors:

In healthy volunteers, compared with pre-treatment values, piracetam up to 9.6 g reduced plasma levels of fibrinogen and von Willebrand's factors (VIII : C; VIII R : AG; VIII R : vW) by 30 to 40 %, and increased bleeding time.

In patients with both primary and secondary Raynaud phenomenon, compared with pre-treatment values, piracetam 8 g/d during 6 months reduced plasma levels of fibrinogen and von Willebrand's factors (VIII : C; VIII R : AG; VIII R : vW (RCF)) by 30 to 40 %, reduced plasma viscosity, and increased bleeding time.

5.2 Pharmacokinetic properties

Piracetam is rapidly and almost completely absorbed. Peak plasma levels are reached within 1.5 hours after administration. The extent of oral bioavailability, assessed from the Area Under Curve (AUC), is close to 100% for capsules, tablets and solution. Peak levels and AUC are proportional to the dose given. The volume of distribution of piracetam is 0.7 L/kg, and the plasma half-life is 5.0 hours, in young adult men. Piracetam crosses the blood-brain and the placental barrier and diffuses across membranes used in renal dialysis. Up to now, no metabolite of piracetam has been found. Piracetam is excreted almost completely in urine and the fraction of the dose excreted in urine is independent of the dose given. Excretion half-life values are consistent with those calculated from plasma / blood data. Clearance of the compound is dependent on the renal creatinine clearance and would be expected to diminish with renal insufficiency.

5.3 Preclinical safety data

Single doses of piracetam yielded LD 50 values at 26 g/kg in mice but LD 50 values were not reached in rats. In dogs, clinical signs after acute oral dosing were mild and lethality was not observed at the maximum tested dose of 10 g/kg.

Repeated oral treatment for up to 1 year in dogs (10 g/kg) and 6 months in rats (2 g/kg) was very well tolerated: no target organ toxicity or signs of (irreversible) toxicity were clearly demonstrated. Safe dose levels represent a multiple of the maximum intended human daily dose of 0.4 g/kg.

In terms of exposure (C max) safe levels obtained in the rat and the dog represent respectively 8 fold and 50 fold of the maximum human therapeutic level. AUC levels obtained in the same animals were a multiple of the human AUC level at the maximum intended daily dose.

The only change which might eventually be attributed to chronic treatment in male, but not in female, rats was an increase of the incidence over control animals of progressive glomerulonephrosis at the dose of 2.4 g/k/day given for 112 weeks.

Although piracetam crosses the placenta into the foetal circulation, no teratogenic effects were observed at dose levels up to 4.8 g/kg/day (mice, rats) and 2.7 g/kg/day (rabbits). Furthermore, the compound affects neither fertility nor the peri- or postnatal development of the pregnancy at doses up to 2.7 g/kg/day.

Piracetam was found to be devoid of any mutagenic or clastogenic activity and does not represent any genotoxic or carcinogenic risk to man.

6. Pharmaceutical particulars
6.1 List of excipients

Macrogol 6000.

Colloidal anhydrous silica.

Magnesium stearate

Croscarmellose sodium

Hypromellose (E464)

Titanium dioxide (E171)

Macrogol 400

6.2 Incompatibilities

None known.

6.3 Shelf life

Four (4) years.

6.4 Special precautions for storage

None.

6.5 Nature and contents of container

Blister pack in an outer cardboard carton (90 tablets per carton).

6.6 Special precautions for disposal and other handling

None.

Pira Pro The original nootropic

Supplement facts:

Serving size: 2 tablets

Servings per container: 50

Amount per serving: Piracetam 1600mg*

*% daily value not established.

Other ingredients: starch, di-basic, calcium phosphate, micro-crystalline cellulose phosphate, cross-povidone, talcum, magnesium stearate, cross-carmelose sodium.

Piracetam is the original nootropic that has been shown to be effective in improving states of short term memory and attention; it is particularly noted for its ability to enhance clarity of thought.

Directions: Take 1 or 2 tablets twice daily, or as directed by your physician.

Disclaimer: This product and its statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease.

Important: Keep in cool, dark conditions, out of the reach of children, and consume before end of expiry date. Not for use by pregnant or lactating women.

Note: this product does not contain any GMO substances. It is suitable for vegetarians.

Formulated and distributed by Profound Products

Check our shipping rates

Country
Please note that S&H costs are per order, not per product.

What our customers say